News >

Nivolumab Combo Misses PFS Endpoint in Newly Diagnosed MGMT-Methylated GBM

Gina Columbus @ginacolumbusonc
Published: Thursday, Sep 05, 2019

Fouad Namouni, MD, head, Oncology Development, Bristol-Myers Squibb

Fouad Namouni, MD
The combination of nivolumab (Opdivo) plus standard temozolomide and radiation therapy did not show a statistically significant improvement in progression-free survival (PFS) compared with temozolomide/radiation therapy alone in patients with newly diagnosed glioblastoma multiforme (GBM) that is O6-methylguanine-DNA methyltransferase (MGMT)-methylated, missing one of the primary endpoints of the phase III CheckMate-548 trial.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Overcoming Clinical Inertia in Glioblastoma Multiforme: The Experts Weigh-In on Recent Data Sets and Next Steps to Move the Field ForwardDec 21, 20191.5
Publication Bottom Border
Border Publication
x